Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas C Yoder

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|July 11, 2012
Preparation of unnatural N-to-N and C-to-C protein fusionsMartin D Witte, Juan J Cragnolini, Stephanie K Dougan, et al.
Journal of the American Chemical Society|July 21, 2009
Site-specific N- and C-terminal labeling of a single polypeptide using sortases of different specificityJohn M Antos, Guo-Liang Chew, Carla P Guimaraes, et al.
Bioorganic & Medicinal Chemistry Letters|July 28, 2019
Design, synthesis and evaluation of novel, potent DNA alkylating agents and their antibody-drug conjugates (ADCs)Emily E Reid, Katie E Archer, Manami Shizuka, et al.
Bioconjugate Chemistry|November 21, 2019
Site-Specific Conjugation of the Indolinobenzodiazepine DGN549 to Antibodies Affords Antibody-Drug Conjugates with an Improved Therapeutic Index as Compared with Lysine ConjugationChen Bai, Emily E Reid, Alan Wilhelm, et al.
Bioconjugate Chemistry|May 14, 2016
Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid ConjugatesJose F Ponte, Xiuxia Sun, Nicholas C Yoder, et al.
Mabs|January 12, 2016
Microscale screening of antibody libraries as maytansinoid antibody-drug conjugatesKalli C Catcott, Molly A McShea, Carl Uli Bialucha, et al.
Molecular Pharmaceutics|July 10, 2019
A Case Study Comparing Heterogeneous Lysine- and Site-Specific Cysteine-Conjugated Maytansinoid Antibody-Drug Conjugates (ADCs) Illustrates the Benefits of Lysine ConjugationNicholas C Yoder, Chen Bai, Daniel Tavares, et al.
Blood Advances|April 18, 2018
A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cellsYelena Kovtun, Gregory E Jones, Sharlene Adams, et al.
ACS Medicinal Chemistry Letters|August 16, 2019
Effect of Linker Stereochemistry on the Activity of Indolinobenzodiazepine Containing Antibody-Drug Conjugates (ADCs)Emily E Reid, Katie E Archer, Manami Shizuka, et al.
Bioconjugate Chemistry|April 9, 2017
Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid ConjugatesXiuxia Sun, Jose F Ponte, Nicholas C Yoder, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Proceedings of the National Academy of Sciences of the United States of America|July 11, 2012
Preparation of unnatural N-to-N and C-to-C protein fusionsMartin D Witte, Juan J Cragnolini, Stephanie K Dougan, et al.
Journal of the American Chemical Society|July 21, 2009
Site-specific N- and C-terminal labeling of a single polypeptide using sortases of different specificityJohn M Antos, Guo-Liang Chew, Carla P Guimaraes, et al.
Bioorganic & Medicinal Chemistry Letters|July 28, 2019
Design, synthesis and evaluation of novel, potent DNA alkylating agents and their antibody-drug conjugates (ADCs)Emily E Reid, Katie E Archer, Manami Shizuka, et al.
Bioconjugate Chemistry|November 21, 2019
Site-Specific Conjugation of the Indolinobenzodiazepine DGN549 to Antibodies Affords Antibody-Drug Conjugates with an Improved Therapeutic Index as Compared with Lysine ConjugationChen Bai, Emily E Reid, Alan Wilhelm, et al.
Bioconjugate Chemistry|May 14, 2016
Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid ConjugatesJose F Ponte, Xiuxia Sun, Nicholas C Yoder, et al.
Mabs|January 12, 2016
Microscale screening of antibody libraries as maytansinoid antibody-drug conjugatesKalli C Catcott, Molly A McShea, Carl Uli Bialucha, et al.
Molecular Pharmaceutics|July 10, 2019
A Case Study Comparing Heterogeneous Lysine- and Site-Specific Cysteine-Conjugated Maytansinoid Antibody-Drug Conjugates (ADCs) Illustrates the Benefits of Lysine ConjugationNicholas C Yoder, Chen Bai, Daniel Tavares, et al.
Blood Advances|April 18, 2018
A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cellsYelena Kovtun, Gregory E Jones, Sharlene Adams, et al.
ACS Medicinal Chemistry Letters|August 16, 2019
Effect of Linker Stereochemistry on the Activity of Indolinobenzodiazepine Containing Antibody-Drug Conjugates (ADCs)Emily E Reid, Katie E Archer, Manami Shizuka, et al.
Bioconjugate Chemistry|April 9, 2017
Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid ConjugatesXiuxia Sun, Jose F Ponte, Nicholas C Yoder, et al.
Pageof 3